This 12-month open-label,but dose-blinded extension phase,
evaluated the safety and tolerability of flexibly-dosededivoxetine (6, 9, 12 or 18 mg once
daily) inpatients (N=397)
with major depressive disorder, who completed the 10-week randomized,
double-blind, placebo-controlled acute phase of the study.All patients were
treated with edivoxetine during the extension phase.The mean age of the patients was 45
years, and most were whitefemales.
Safety evaluations included assessment of treatment-emergent adverse events
(TEAEs), laboratory and vital sign measures, and suicidality. Within-group
t-tests based on a 2-sided significance level of 0.05 and 95% confidence levels
were used to assess whether changes from baseline were statistically
significant from zero. The overall completion rate was 54%. Adverse event was
the most common (14.4%) reason for discontinuation, which included blood
pressure increased (1.3%), heart rate increased (1.3%), anxiety (1.0%), and
tachycardia (1.0%). At least 1 TEAE was reported by 72.3% of patients, of which
headache (10.8%) and hyperhidrosis (10.1%) were the most common; 2.8% of
patients had ≥1 serious adverse events, and there were no completed suicides.No
Stahl, S.M., Zhang, L., Damatarca, C. and Grady, M. (2003) Brain Circuits Determine Destiny in Depression: A Novel Approach to the Psychopharmacology of Wakefulness, Fatigue, and Executive Dysfunction in Major Depressive Disorder. Journal of Clinical Psychiatry, 64(Suppl 14), 6-17.
Pangallo, B., Dellva, M.A., D’Souza, D.N., Essink, B., Russell, J. and Goldberger, C. (2011) A Randomized, Double-Blind Study Comparing LY2216684 and Placebo in the Treatment of Major Depressive Disorder. Journal of Psychiatric Research, 45, 748-755. http://dx.doi.org/10.1016/j.jpsychires.2011.03.014
Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R. and Dunbar, G.C. (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): The Development and Validation of a Structured Diagnostic Psychiatric Interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59(Suppl 20), 22-33.
Williams, J.B., Kobak, K.A., Bech, P., Engelhardt, H., Evans, K., Lipsitz, J., Olin, J., Pearson, J. and Kalali, A. (2008) The GRID-HAMD: Standardization of the Hamilton Depression Rating Scale. International Clinical Psychopharmacology, 23, 120-129. http://dx.doi.org/10.1097/YIC.0b013e328 2f948f5
Posner, K., Brown, G.K., Stanley, B., Brent, D.A., Yershova, K.V., Oquendo, M.A., Currier, G.W., Melvin, G.A., Greenhill, L., Shen, S. and Mann, J.J. (2011) The Columbia-Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings from Three Multisite Studies with Adolescents and Adults. American Journal of Psychiatry, 168, 1266-1277. http://dx.doi.org/10.1176/appi.ajp.2011.10111704
Matza, L.S., Phillips, G.A., Revicki, D.A., Murray, L. and Malley, K.G. (2011) Development and Validation of a Patient-Report Measure of Fatigue Associated with Depression. Journalof Affective Disorders, 134, 294-303.
Dubé, S., Dellva, M.A., Jones, M., Kielbasa, W., Padich, R., Saha, A. and Rao, P. (2010) A Study of the Effects of LY2216684, a Selective Norepinephrine Reuptake Inhibitor, in the Treatment of Major Depression. Journal of Psychiatric Research, 44, 356-363. http://dx.doi.org/10.1016/j.jpsychires. 2009.09.013
Versiani, M., Mehilane, L., Gaszner, P. and Arnaud-Castiglioni, R. (1999) Reboxetine, a Unique Selective NRI, Prevents Relapse and Recurrence in Long-Term Treatment of Major Depressive Disorder. Journal of Clinical Psychiatry, 60, 400-406. http://dx.doi.org/10.4088/JCP.v60n0610
Schweitzer, I., Burrows, G., Tuckwell, V., Polonowita, A., Flynn, P., George, T., Theodoros, M. and Mitchell, P. (2001) Sustained Response to Open-Label Venlafaxine in Drug-Resistant Major Depression. Journal of Clinical Psychopharmacology, 21, 185-189. http://dx.doi.org/10.1097/00004714-200104000-00010
Raskin, J., Goldstein, D.J., Mallinckrodt, C.H. and Ferguson, M.B. (2003) Duloxetine in the Long-Term Treatment of Major Depressive Disorder. Journal of Clinical Psychiatry, 64, 1237-1244. http://dx.doi.org/10.4088/JCP.v64n1015
Wohlreich, M.M., Mallinckrodt, C.H., Watkin, J.G. and Hay, D.P. (2004) Duloxetine for the Long-Term Treatment of Major Depressive Disorder in Patients Aged 65 and Older: An Open-Label Study. BMC Geriatrics, 7, 4-11.
Wade, A., Despiegel, N. and Heldbo Reines, E. (2006) Escitalopram in the Long-Term Treatment of Major Depressive Disorder. Annals of Clinical Psychiatry, 18, 83-89. http://dx.doi.org/10.1080/10401230600614447
Chokka, P. and Legault, M. (2008) Escitalopram in the Treatment of Major Depressive Disorder in Primary-Care Settings: An Open-Label Trial. Depression and Anxiety, 25, E173-E181. http://dx.doi.org/10.1002/da.20458
Dunner, D.L., Wilson, M., Fava, M., Kornstein, S., Munoz, R., O’Reardon, J., Trivedi, M. and Wohlreich, M. (2008) Long-Term Tolerability and Effectiveness of Duloxetine in the Treatment of Major Depressive Disorder. Depression and Anxiety, 25, E1-E8. http://dx.doi.org/10.1002/da.20339
Tourian, K.A., Pitrosky, B., Padmanabhan, S.K. and Rosas, G.R. (2011) A 10-Month, Open-Label Evaluation of Desvenlafaxine in Outpatients with Major Depressive Disorder. Primary Care Companionto CNS Disorders, 13, ii: PCC.10m00977. http://dx.doi.org/10.4088/pcc.10m00977
Mago, R., Forero, G., Greenberg, W.M., Gommoll, C. and Chen, C. (2013) Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study. Clinical Drug Investigations, 33, 761-771. http://dx.doi.org/10.1007/s40261-013-0126-5
Citrome, L. (2013) Levomilnacipran for Major Depressive Disorder: A Systematic Review of the Efficacy and Safety Profile for This Newly Approved Antidepressant—What Is the Number Needed to Treat, Number Needed to Harm and Likelihood to be Helped or Harmed? International Journal of Clinical Practice, 67, 1089-10104.
Serretti, A. and Chiesa, A. (2009) Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A MetaAnalysis. Journal of Clinical Psychopharmacology, 29, 259-266. http://dx.doi.org/10.1097/JCP.0b013e3181a5233f